HC Wainwright Has Negative Outlook of XFOR FY2024 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – HC Wainwright lowered their FY2024 EPS estimates for X4 Pharmaceuticals in a research note issued on Thursday, November 14th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.66) for the year, down from their previous estimate of ($0.60). HC Wainwright currently has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.04 EPS.

Separately, Stifel Nicolaus reduced their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 8.3 %

NASDAQ XFOR opened at $0.37 on Monday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 6.04 and a current ratio of 4.89. The firm has a 50-day simple moving average of $0.58 and a 200 day simple moving average of $0.74. X4 Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $1.60. The stock has a market cap of $63.12 million, a PE ratio of -4.48 and a beta of 0.39.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in XFOR. GSA Capital Partners LLP acquired a new position in X4 Pharmaceuticals in the third quarter worth about $340,000. K2 Principal Fund L.P. acquired a new stake in shares of X4 Pharmaceuticals during the second quarter worth approximately $284,000. AQR Capital Management LLC increased its holdings in shares of X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after buying an additional 388,115 shares in the last quarter. State Street Corp increased its holdings in shares of X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares in the last quarter. Finally, Barclays PLC increased its holdings in shares of X4 Pharmaceuticals by 196.0% during the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock worth $185,000 after buying an additional 183,861 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

Insider Buying and Selling

In related news, COO Mary Dibiase sold 67,695 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.57, for a total value of $38,586.15. Following the completion of the transaction, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. This represents a 13.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Paula Ragan sold 239,436 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $131,689.80. Following the completion of the transaction, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at $581,742.15. This trade represents a 18.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 580,800 shares of company stock valued at $321,447 over the last quarter. Corporate insiders own 1.62% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.